Besifovir dipivoxil maleate
Spectrum Of Activity
150 mg PO once daily + L-carnitine 660 mg
Safety and efficacy in pediatric patients <18y of age have not been established
Compensated cirrhosis No dose adjustment
Decompensated cirrhosis No data
Mild renal impairment Use with caution
Moderate to severe renal impairment No data
Type B viral hepatitis, chronic
Monitor liver and renal function.
Monitor serum L-carnitine levels.
Test for HIV antibodies prior to treatment.
Increased liver enzymes
Skin reactions (e.g. hives, rash, dermatitis)
Malignant or unspecified neoplasm
Drugs that reduce renal function or compete for active tubular secretion
Antimicrobial class: Antiviral agent
Average serum half life: 2-3 hours (Besifovir), 45-90 hours (LB80317)
Precautions: Severe acute exacerbations of HBV have been reported in patients who discontinued anti-hepatitis B therapy; monitoring recommended with clinical and laboratory follow-up.